Clinical Trial Update: A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating JBI-802 alone or in combination with pembrolizumab for non-small cell lung cancer with an STK11 mutation; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JBI-802
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: The Christ Hospital | Conditions: Lung Cancer (NSCLC) | Phase 2 | Status: RECRUITING